SCHEDULE: ARK & Wood Boost Intellia Therapeutics Stake to 12.27%

ARK Investment Management LLC and Catherine D. Wood have jointly filed an Amendment No. 8 on Schedule 13G, reporting a combined beneficial ownership of 12.27% in Intellia Therapeutics, Inc.

Summary

• ARK Investment Management LLC and Catherine D. Wood jointly filed an Amendment No. 8 on Schedule 13G for Intellia Therapeutics, Inc.
• They report beneficial ownership of 14,207,324 shares of Common Stock as of December 31, 2025.
• This aggregate amount represents 12.27% of the class of securities.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• ARK Innovation ETF, a series of a Delaware statutory trust, holds an interest exceeding 5% of the class.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it confirms continued strong institutional backing from a prominent investor in the biotech space, suggesting ongoing confidence in Intellia's long-term prospects.

Positives

• Continued significant institutional ownership by a prominent investment firm (ARK) and its CEO (Catherine D. Wood) indicates ongoing conviction in Intellia Therapeutics.
• The filing confirms the shares are held in the ordinary course of business, not for activist purposes, suggesting a long-term investment perspective.

Future Outlook

This Schedule 13G filing does not contain specific forward-looking statements or guidance from Intellia Therapeutics, Inc. It primarily reports the beneficial ownership stake of ARK Investment Management LLC and Catherine D. Wood as of December 31, 2025.

Management Comments

• ARK Investment Management LLC and Catherine D. Wood do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file an Amendment No. 8 on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Amendment No. 8 on Schedule 13G shall be filed on behalf of each of them.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that ARK Investment Management, led by Catherine D. Wood, is a prominent investor in disruptive innovation, particularly within the biotechnology and gene editing sectors. Their continued significant stake in Intellia Therapeutics, a leader in CRISPR-based gene editing, underscores their long-term conviction in the potential of this technology and Intellia's position within the competitive landscape. This filing reinforces ARK's strategic focus on companies at the forefront of scientific advancement.

Comparison to Industry Standards

• ARK's 12.27% stake in Intellia Therapeutics is a substantial position for an institutional investor, indicating high conviction. For comparison, other major institutional investors in the biotechnology sector often hold stakes ranging from 2% to 10% in their portfolio companies, depending on market capitalization and investment strategy.
• Catherine D. Wood's personal and shared dispositive power over the entire 12.27% stake, alongside ARK Investment Management LLC, aligns with the firm's active management style and her direct involvement in investment decisions for funds like the ARK Innovation ETF, which also holds a significant interest in Intellia.
• The filing as a Schedule 13G, rather than a 13D, confirms a passive investment intent, which is standard for many large institutional holders who do not seek to influence control, differentiating it from activist investors who typically file 13D for larger, more influential stakes.

Related Party Transactions

• ARK Innovation ETF, a series of a Delaware statutory trust, is known to have an interest in the securities reported herein in excess of 5 percent.

Stakeholder Impact

• Shareholders: Continued significant institutional ownership by ARK may provide a level of confidence and stability, potentially attracting other investors.
• Company Management: The substantial stake held by ARK and Catherine D. Wood indicates a significant institutional presence on the shareholder register, which management will likely consider in strategic decisions.

Next Steps

• Intellia Therapeutics, Inc. will continue its research and development activities in gene editing.
• ARK Investment Management LLC and Catherine D. Wood will continue to monitor their investment in Intellia Therapeutics, Inc. and file further amendments as required by SEC regulations.

Key Dates

Recommendation

This filing is a routine disclosure of beneficial ownership by a major institutional investor. While it confirms continued strong conviction from ARK Investment Management, it does not provide new operational or financial data about Intellia Therapeutics that would warrant a change in investment thesis. Investors should hold their positions and await further company-specific news or financial reports for actionable insights.

Keywords

Intellia Therapeutics, ARK Investment Management, Catherine D. Wood, Schedule 13G, Beneficial Ownership, NTLA, Biotechnology, Gene Editing, CRISPR